ZVSA
ZyVersa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.11
+14.55%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.11
From 52W high−58.00%
Volume300.00
Market cap$8.78M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.11
From 52W high
−58.00%
Volume
300.00
Market cap
$8.78M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−36.7x
P/E (TTM)
—
RSI (14)
58.3
MomentumView details →
1D Return
+14.55%
YTD Return
−15.37%
SummaryUpdated Mar 1, 2026
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) is a clinical-stage biopharmaceutical company founded and headquartered in Weston, Florida. The company went public in February 2022 and focuses on developing novel therapeutic treatments for renal (kidney) and inflammatory diseases. As a pre-revenue biotechnology company, ZyVersa is currently advancing two primary drug candidates through clinical development: VAR 200 for kidney diseases and IC 100 for inflammatory conditions.
Similar companies
Latest newsMore news →
No recent news for ZVSA.